🧪 UPDATED DAILY FROM CLINICALTRIALS.GOVSynced Apr 1

Find Clinical Trials for Your Rare Disease

14+ recruiting trials across all rare diseases. Filter by phase, location, and condition.

ℹ
Clinical trial records are synced from ClinicalTrials.gov.
Report missing data
Clear

Showing 14 of 14 recruiting trials for “Neurofibromatosis type 1”

NARecruitingNCT06507748 ↗

A Study to Evaluate the Feasibility of a Physiologic Biomarker to Assess Pain and Other Sensory Problems Using Pupillometry in Participants With Neurofibromatosis Type 1 (NF1)

👨‍⚕️ Pamela L Wolters, Ph.D., National Cancer Institute (NCI)📍 1 site📅 Started Feb 2026View details ↗
Phase 1RecruitingNCT07102394 ↗

Feasibility and Tolerability of IMLYGIC for the Treatment of Cutaneous Neurofibromas in Adults With NF1

👨‍⚕️ Carlos Romo, MD, Johns Hopkins University📍 1 site📅 Started Feb 2026View details ↗
NARecruitingNCT07221331 ↗

Prevalence, Clinical Characteristics, Progression, and Management of Neurofibromatosis Type 1 in Egypt (NF1-Egy)

👨‍⚕️ AstraZeneca Clinical Study Information Center📍 9 sites📅 Started Nov 2025View details ↗
NARecruitingNCT07088991 ↗

Clinical and Demographic Characteristics of Adult p Atients With NEurofibromatosis in RUSsia

👨‍⚕️ AstraZeneca Clinical Study Information Center📍 11 sites📅 Started Jun 2025View details ↗
Phase 1RecruitingNCT06961565 ↗

PAS-004 in Adults Who Have Neurofibromatosis Type 1 With Plexiform Neurofibromas

👨‍⚕️ Tiago R Marques, MD, Pasithea Therapeutics Corp.📍 5 sites📅 Started May 2025View details ↗
NARecruitingNCT06880991 ↗

Development of Patient-Reported Outcome Measures Assessing Tumor Visibility and Appearance Concerns in Neurofibromatosis Type 1: A Qualitative Study

👨‍⚕️ Staci M Peron, Ph.D., National Cancer Institute (NCI)📍 1 site📅 Started Apr 2025View details ↗
Phase 2RecruitingNCT06541847 ↗

A Phase 2, Open-Label Study to Evaluate the Safety and Effects of HLX-1502 in Patients With Neurofibromatosis Type 1

👨‍⚕️ Miriam Bornhorst, Lurie's Children's Hospital📍 13 sites📅 Started Feb 2025View details ↗
NARecruitingNCT06222203 ↗

Surveillance for Malignant Transformation of Neurofibromatosis Type 1 (NF1) Related Peripheral Nerve Sheath Tumors (PNST)

👨‍⚕️ Brigitte C Widemann, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Oct 2024View details ↗
RecruitingNCT06515860 ↗

Neurofibromatosis Type 1 Tumor Early Detection Study

👨‍⚕️ David T Miller, MD, PhD, Boston Children's Hospital📍 1 site📅 Started Aug 2024View details ↗
NARecruitingNCT04763109 ↗

Identification of Pre-Malignant Lesions In Pediatric Patients With Neurofibromatosis Type 1 Using Novel Magnetic Resonance Imaging Techniques Paired With Artificial Intelligence

👨‍⚕️ Nicole Baca, MD, Cedars-Sinai Medical Center📍 1 site📅 Started Jul 2022View details ↗
Enrolling by InvitationNCT05238909 ↗

Developing Biomarkers of Plexiform Tumor Burden in Patients With Neurofibromatosis-Type 1

👨‍⚕️ Carlos Prada, MD, Ann & Robert H Lurie Children's Hospital of Chicago📍 1 site📅 Started Mar 2022View details ↗
Phase 1RecruitingNCT04750928 ↗

Cyclin-Dependent Kinase (CDK)4/6 Inhibitor Abemaciclib for Neurofibromatosis Type I (NF1) Related Atypical Neurofibromas

👨‍⚕️ Brigitte C Widemann, M.D., National Cancer Institute (NCI)📍 1 site📅 Started Nov 2021View details ↗
Phase 2RecruitingNCT05331105 ↗

HL-085 in Adults With Neurofibromatosis Type 1 (NF1) and Inoperable Plexiform Neurofibromas

👨‍⚕️ Hongqi Tian, Ph.D, Shanghai Kechow Pharma, Inc.📍 1 site📅 Started Oct 2021View details ↗
NARecruitingNCT00598351 ↗

Natural History Study of Patients With Neurofibromatosis Type 2

👨‍⚕️ Prashant Chittiboina, M.D., National Institute of Neurological Disorders and Stroke (NINDS)📍 1 site📅 Started Mar 2008View details ↗

Get alerts when new trials open

Create a free account to follow conditions and receive trial notifications.

Create free account →